EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This laboratory study is using EF5 to evaluate tumor hypoxia in patients with high-grade soft tissue sarcoma or mouth cancer. Using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)

Criteria

Inclusion Criteria:

• Histologically confirmed high-grade soft tissue sarcoma (STS) of the trunk or extremity or squamous cell carcinoma of the oral cavity for which surgical biopsy or resection is standard initial therapy

• Clinical imaging of mass that is likely to be STS or squamous cell carcinoma of the head and neck allowed if surgery is indicated prior to definitive diagnosis

• Planned resection and standard oncologic treatment

• No known distant metastatic disease

• ECOG 0-2

• WBC at least 2,000/mm^3

• Platelet count at least 100,000/mm^3

• Bilirubin less than 2.0 mg/dL

• Creatinine less than 2.0 mg/dL OR creatinine clearance at least 50 mL/min

• No significant cardiac condition that would preclude study compliance

• Weight no greater than 130 kg

• No grade III or IV peripheral neuropathy

• No other medical condition that would preclude study compliance

• Not pregnant or nursing

• Fertile patients must use effective contraception

• See Disease Characteristics

• No chemotherapy within 3 months before planned surgery

• Preoperative radiotherapy allowed for STS

• No radiotherapy within 3 months before planned surgery

• No other concurrent investigational agents